Reduced stroke risk for AF patients taking Bayer's Xarelto, new data shows

New data shows reduced risk of ischemic stroke and intracranial hemorrhage (ICH) among patients with non-valvular atrial fibrillation (AF) receiving German pharma major Bayer’s (BAYN: DE) Xarelto (rivaroxaban), compared with those taking warfarin.

The findings are from the real-world study REVISIT-US, involving almost 23,000 patients, and were presented at the 2nd Annual Congress of the European Cardiac Arrhythmia Society.

These results confirm the positive benefit-risk profile of rivaroxaban as demonstrated in the real-world, non-interventional XANTUS study, which included more than 6,500 patients across the UK, Europe, Israel and Canada.